Sumoylation In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
| Property |
Value |
| Modifier |
SUMO (1, 2, 3, 4) |
| Enzymes |
E1 (SAE1/UBA2), E2 (UBC9), E3 ligases |
| Target |
Lysine residues |
| Reversal |
SENP proteases |
SUMOylation is a reversible post-translational modification involving Small Ubiquitin-like Modifier (SUMO) proteins. This pathway plays crucial roles in protein stability, localization, and function, with dysregulation implicated in multiple neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
- E1 - Activating enzyme: SAE1/UBA2 heterodimer activates SUMO in an ATP-dependent manner
- E2 - Conjugating enzyme: UBC9 directly transfers SUMO to target proteins
- E3 - Ligases: PIAS family proteins (PIAS1, PIASx, PIASy), RanBP2, and others provide substrate specificity
- SENPs: SUMO-specific proteases (SENP1-7) remove SUMO for reversibility
The canonical SUMOylation consensus sequence is ΨKxE (where Ψ is a hydrophobic residue like I, L, V). Additional motifs include reverse consensus and phosphorylated SUMO consensus motifs.
SUMOylation of APP influences amyloid-beta generation:
- SUMOylation at K587 reduces amyloidogenic processing
- PIAS1-mediated SUMOylation decreases amyloid-beta secretion
- Dysregulation contributes to amyloid plaque formation
SUMOylation promotes tau aggregation:
- SUMOylated tau is more prone to form neurofibrillary tangles
- SENP1 overexpression reduces tau aggregation
- SUMOylation affects tau phosphorylation and degradation
SUMOylation modulates synaptic protein turnover:
- Synaptic receptors and scaffolding proteins are SUMO targets
- NMDA receptor SUMOylation regulates synaptic plasticity
- PSD-95 SUMOylation affects synaptic stability
SUMOylation affects alpha-synuclein pathology:
- SUMO1 conjugation reduces aggregation but may impair clearance
- SUMO2/3 conjugation promotes inclusions
- Parkin E3 ligase activity modulated by SUMOylation
¶ Parkin and PINK1
The PINK1/Parkin mitophagy pathway involves SUMOylation:
- PINK1 stabilizes on damaged mitochondria
- Parkin SUMOylation enhances its E3 ligase activity
- SENP5 regulates mitochondrial dynamics through deSUMOylation
Oxidative stress sensor DJ-1 is regulated by SUMOylation:
- SUMOylation protects against oxidative stress
- Parkinson's disease-associated mutations affect SUMOylation
- Therapeutic strategies target DJ-1 SUMOylation
SUMOylation of mutant huntingtin:
- Promotes protein aggregation
- Increases toxicity
- Affects nuclear localization
SUMOylation affects gene expression:
- Histone SUMOylation promotes repressive chromatin states
- Transcription factor SUMOylation alters target gene expression
- Coactivator/co-repressor SUMOylation modulates transcriptional programs
SUMOylation impacts mitochondrial health:
- Mitochondrial proteins are SUMO targets
- Mitophagy regulators modified by SUMO
- Energy metabolism affected
TDP-43 aggregates in most ALS cases:
- SUMOylation influences TDP-43 aggregation
- SENP1 can reduce TDP-43 inclusions
- Nuclear export regulated by SUMOylation
ALS-associated SOD1 mutations:
- SUMOylation affects mutant SOD1 stability
- Aggregate formation influenced by SUMO
- Therapeutic targeting possible
FUS pathology in ALS/FTD:
- SUMOylation affects nuclear import/export
- Stress granule dynamics regulated
- Mutations affect SUMOylation patterns
SUMOylation regulates protein homeostasis:
- Proteasomal degradation: SUMO chains can signal for degradation
- Autophagy: Selective autophagy of SUMOylated substrates
- Protein solubility: SUMO maintains protein solubility
SUMOylation affects gene expression:
- Histone modification alters chromatin state
- Transcription factor activity modulated
- Co-activator/co-repressor function affected
SUMOylation impacts mitochondrial biology:
- Dynamics: Fusion/fission regulators modified
- Import: Protein trafficking affected
- Quality control: Mitophagy regulation
| Approach |
Target |
Potential |
| E1/E2 agonists |
SUMOylation enzymes |
Neuroprotection |
| SENP inhibitors |
DeSUMOylation |
Reduce aggregation |
| Gene therapy |
SUMO expression |
Experimental |
- α-Synuclein: Prevent harmful SUMOylation patterns
- Tau: Promote protective modifications
- Huntingtin: Reduce aggregation-prone forms
- TDP-43: Modulate aggregation propensity
Small molecules targeting SUMOylation:
- TAK-981 (subasumstat) - Phase 1/2 for cancer, potential for neurodegeneration
- Various SENP inhibitors in development
The study of Sumoylation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- SUMOylation in Neurodegenerative Diseases - Progress in Molecular Biology (2024)
- SUMO and Neurodegeneration - Cellular and Molecular Life Sciences (2022)
- SUMOylation of α-Synuclein in Parkinson's Disease - J Neurochem (2019)
- SUMOylation in Alzheimer's Disease - Mol Brain (2020)
- Targeting SUMOylation in Parkinson's Disease - Neurobiology of Disease (2019)
- SUMOylation in Huntington's Disease - Exp Neurol (2022)
- TDP-43 SUMOylation in ALS - Acta Neuropathol (2021)
- Therapeutic Potential of SUMOylation Modulators - J Med Chem (2023)
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 29%